This educational program provides a series of case-based scenarios with accompanying resources to help physicians navigate the clinical implications for the use of biosimilars for inflammatory bowel disease (IBD). The focus of the case scenarios will be to highlight the needs of IBD patients at different points of care, including beginning treatment, a potential payor-necessitated switch to biosimilars and general questions about switching.
This is the first in our series of four cases related to biosimilars in IBD care.
Here, we’ll be meeting a 19-year-old biologic-naïve patient who was recently diagnosed with severe ulcerative colitis. She is at high risk for colectomy in the near future and is starting on a biosimilar right away.
Sign in to access
After you sign in, please click the "Launch" button on the top of this page to access this course.
Product features
- Case-based patient scenarios
- Knowledge checks
- Responsive design adapts to your PC, laptop, tablet or smartphone
Learning objectives
After completing this activity, participants should be able to:
- Address the needs of IBD patients considering biosimilar therapies at different points in care through service delivery method best practices.
- Apply practice recommendations for patient information and consultation during biosimilar adoption/implementation phase.
- Define and use specific terms related to biosimilars in conversations with patients and caregivers.
- Share resources with patients that inform and empower participation in shared-decision making about biosimilars or biologics in their IBD treatment.
Course faculty
Mark T. Osterman, MD, MSCE- Chair
Adam S. Cheifetz, MD
Douglas C. Wolf, MD
Pricing
|
Member
|
Nonmember
|
| $Free |
$Free |
Accreditation and designation statement
CME statement
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates the online activity NP Pharmacology: IBD, including the mock exam, for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Disclosures
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:
Dr. Osterman:
AbbVie- Advisory Committee/Review Panel (Consulting Fee)
Janssen- Advisory Committee/Review Panel (Consulting Fee)
Merck- Advisory Committee/Review Panel (Consulting Fee)
Takeda- Advisory Committee/Review Panel (Consulting Fee)
Pfizer- Advisory Committee/Review Panel (Consulting Fee)
UCB- Grant/Research Support (Salary)
Dr. Cheifetz:
Inform Diagnostics- Grant/Research Support (Consulting Fee)
AbbVie- Consulting (Consulting Fee)
Janssen- Consulting (Consulting Fee)
Takeda- Consulting (Consulting Fee)
Pfizer- Consulting (Consulting Fee)
Samsung- Consulting (Consulting Fee)
Arena- Consulting (Consulting Fee)
Bacainn- Consulting (Consulting Fee)
Emd Serono- Consulting (Consulting Fee)
Arsanis- Consulting (Consulting Fee)
Grifols- Consulting (Consulting Fee)
Prometheus- Consulting (Consulting Fee)
Dr. Wolf:
No conflict of interest disclosures reported
